If Everyone Hates the FDA Approval Process, Let’s Fix It

A new solution, “adaptive licensing,” has great potential but faces big obstacles.

by

Dan Ollendorf

by

Dan Ollendorf

October 18, 2013

There is one certainty about the current regulatory process for drug approval in the United States and Europe: No one likes it.

DO

Dan Ollendorf is the chief review officer at the Institute for Clinical & Economic Review, where he leads efforts to review and synthesize evidence on new and emerging drugs, devices, and health-system interventions.

Partner Center